Market Overview

Bonti Announces Company Presentation At Renowned And Popular 2017 BIO International Convention


Bonti, a privately-held, clinical-stage biotechnology company, today
announced a corporate presentation by its CEO at the 2017 BIO
International Convention in the Business Forum on Monday, June 19th
at 4:15 PM (local time) in San Diego, CA. Mr. Hasan will highlight
Bonti's lead product candidate, EB-001, which is a novel botulinum
neurotoxin with a unique target profile, characterized by fast onset of
action and short duration of effect. The clinical safety and efficacy of
EB-001 is being investigated in Phase 2 clinical trials.

EB-001's target indications will address areas of unmet medical needs,
where the molecule's product profile is highly beneficial for
opportunities in the treatment of musculoskeletal pain in both surgical
and non-surgical therapeutic settings. A biologic that treats root cause
and does so without the side effects of opioids, EB-001 is seen as a
potential solution to the current opioid epidemic in the U.S. In
addition, the unique profile of EB-001 could be used in many new and
existing aesthetic settings and would be complementary to existing
products, potentially expanding the market significantly.

Founded in 2015, Bonti has advanced rapidly from its early development
stages to already having its lead product candidate, EB-001, in human
clinical testing. Bonti's co-founder and CEO will outline how the
company established and attained aggressive milestones, describe its
innovative development pipeline and comment on the firm's future
direction and goals. Based on 2016's BIO attendance, over 16,000
biotechnology and pharmaceutical leaders are expected this year at the
self-described Global Event for Biotechnology.

"We are elated for the opportunity to present Bonti and EB-001 to the
global audience at this conference and to be considered among the most
innovative technologies in biotech today," conveyed Fauad Hasan,
co-founder and CEO of Bonti. "It is a privilege to have been invited to
speak at the 2017 BIO International Convention where all facets of
biotechnology – from entrepreneurial companies developing a first
product, like us, to Fortune 100 multinational enterprises – are
represented. We're also grateful for the honor of having been chosen as
one of the finalist companies for the Buzz of BIO competition. We
believe this reflects our aim to build an elite venture to quickly and
successfully develop a novel neurotoxin with a target profile which
offers unique clinical benefits for therapeutic and aesthetic

About EB-001

Bonti's lead product candidate, EB-001, is an investigational botulinum
neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar
to the marketed BoNT/A products though it has a differentiated clinical
profile. EB-001 has a fast onset of action (about 24 hours) and short
duration of effect (about 4 weeks). Currently marketed BoNT/A products
have an onset of action around 3-7 days and a duration of effect around
3-4 months. The unique target clinical profile of EB-001 is well suited
for a vast range of aesthetic and therapeutic uses, including for the
treatment of post-surgical and non-surgical musculoskeletal pain, with
currently unmet needs.

About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging
biotechnology company founded by world class neurotoxin experts with
proven success at Allergan, one of the Fortune 500 fastest growing
pharma companies. This team, with unsurpassed neurotoxin, aesthetic and
pain expertise, is uniquely qualified to develop unprecedented treatment
paradigms driven by a novel neurotoxin platform to become an innovative
leader in both aesthetic and therapeutic markets. By turning the science
of neurotoxins into beneficial patient and healthcare provider
solutions, Bonti will improve lives by successfully addressing key unmet
needs in markets with multi-billion dollar addressable opportunities.

For more information, please visit

View Comments and Join the Discussion!